Clinical trial
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic…
NCT00094055 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00094055 |
|---|---|
| Title | Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer |
| Official title | Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Neoplasms |
| Intervention type | Drug |
| Interventions | AG013736 |
| Enrollment | 60 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Oct 11, 2004 |
| Last update posted | Jun 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: